We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-17.36%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.96B
AUM Growth
-$443M
Cap. Flow
+$558M
Cap. Flow %
18.84%
Top 10 Hldgs %
65.6%
Holding
45
New
14
Increased
9
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$83.3M
2
XLRN
Acceleron Pharma
XLRN
+$66.8M
3
PTCT icon
PTC Therapeutics
PTCT
+$60.4M
4
SAGE
Sage Therapeutics
SAGE
+$57.9M
5
RLMD icon
Relmada Therapeutics
RLMD
+$46.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10.1M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$6.73M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$6.26M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.03M

Sector Composition

Rank Sector Weight
1 Healthcare 87.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$330M 11.15%
24,500,000
– –
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$316M 10.67%
4,112,700
+262,500
+7% +$23.5M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.08B
$270M 9.1%
9,010,413
+184,374
+2% +$4.89M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$201M 6.79%
1,787,000
-78,000
-4% -$10.1M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.9B
$163M 5.5%
1,930,000
-70,000
-4% -$6.03M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.66B
$155M 5.23%
1,585,000
-175,000
-10% -$20M
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$136M 4.57%
4,575,000
+575,000
+14% +$19.5M
KPTI icon
8
Karyopharm Therapeutics
KPTI
$158M
$134M 4.54%
466,667
+73,334
+19% +$20.2M
ARGX icon
9
argenx
ARGX
$55.1B
$123M 4.16%
936,500
– –
CNST
10
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$115M 3.87%
3,650,000
– –
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$101M 3.42%
10,950,000
-250,000
-2% -$2.38M
DCPH
12
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$82.3M 2.78%
2,000,000
+1,500,000
+300% +$83.3M
QURE icon
13
uniQure
QURE
$2.78B
$78.3M 2.64%
1,650,000
-50,000
-3% -$2.87M
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$77.3M 2.61%
+860,000
New +$66.8M
ADVM
15
DELISTED
Adverum Biotechnologies
ADVM
$69.9M 2.36%
715,000
+190,000
+36% +$22.2M
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
$69.2M 2.34%
2,800,000
+800,000
+40% +$29.1M
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$67.3M 2.27%
1,435,000
-105,000
-7% -$6.73M
PTCT icon
18
PTC Therapeutics
PTCT
$6.2B
$53.5M 1.81%
+1,200,000
New +$60.4M
RLMD icon
19
Relmada Therapeutics
RLMD
$547M
$39.2M 1.32%
+1,150,000
New +$46.4M
ATNX
20
DELISTED
Athenex, Inc. Common Stock
ATNX
$37.7M 1.27%
243,750
-19,322
-7% -$4.86M
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$34.7M 1.17%
+4,365,655
New +$33.5M
XENE icon
22
Xenon Pharmaceuticals
XENE
$6.19B
$31.4M 1.06%
2,772,000
+372,000
+16% +$5.3M
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
$30M 1.01%
1,365,000
-195,000
-13% -$6.26M
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$28.7M 0.97%
+1,000,000
New +$57.9M
CUE icon
25
Cue Biopharma
CUE
$123M
$26.5M 0.9%
62,333
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Avoro Capital Advisors held 45 positions worth $2.96B, down 13% from $3.41B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors deployed $558M of net new capital in Q1 2020, opening 14 new positions and adding to 9 existing holdings. Its largest new stake was Acceleron Pharma: 860,000 shares worth $77.3M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20M trimmed.

  • Avoro Capital Advisors's largest Q1 2020 buy was Acceleron Pharma: 860,000 shares worth $77.3M.
  • Avoro Capital Advisors added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020, an estimated $83.3M increase.
  • Avoro Capital Advisors's biggest Q1 2020 reduction was Sarepta Therapeutics, cutting an estimated $20M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $2.96B portfolio in Q1 2020.
  • Avoro Capital Advisors opened 14 new positions and closed 2 in Q1 2020.
  • Avoro Capital Advisors's portfolio value fell 13% quarter-over-quarter to $2.96B.

Based on Avoro Capital Advisors's 13F filing for Q1 2020, filed 15 May 2020.